Muscle Wasting Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Muscle Wasting Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Muscle wasting is evident in diverse pathologies like cancer, chronic kidney disease, heart failure, chronic obstructive pulmonary disease (COPD), and during aging or extended inactivity. Diminished muscle mass and function correlate with increased morbidity and mortality, along with a diminished quality of life. Elevated levels of pro-inflammatory cytokines are frequently observed in the plasma of individuals experiencing muscle wasting conditions, prompting interest in anti-inflammatory drugs as potential treatments. However, the effectiveness of such interventions remains variable and contingent on the specific context of the underlying pathology.
The Muscle Wasting Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Muscle Wasting Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Wasting Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Muscle Wasting Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 27 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Muscle Wasting Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Muscle Wasting Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Muscle Wasting Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aarhus UniversityAcesis Holdings Corp
Aphios Corp
AstraZeneca Plc
Aventi Co Ltd
Catalym GmbH
Centre for Drug Design and Discovery
Endevica Bio Inc
Epitracker Inc
Evive Biotech
Faraday Pharmaceuticals Inc
HEM Pharma Inc
Ildong Pharmaceutical Co Ltd
Immusoft Corp
Imperial College London
Laekna Therapeutics Shanghai Co Ltd
MedAvail Holdings Inc
Metafines Co Ltd
MyoPax GmbH
Novo Nordisk AS
Oregon State University
Pephexia Therapeutics ApS
Senzer Ltd
Siwa Therapeutics Inc
Tvardi Therapeutics Inc
Vanderbilt University
Veru Inc
Viking Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Muscle Wasting Disorders reports